XTER:FRE (Germany)
Business Description
Fresenius SE & Co KGaA
Else-Kroener-Strasse 1, Bad Homburg v.d.H, DEU, 61352
Compare
Compare
Traded in other countries / regions
FRE.Austria
•
FREA.Delisted
•
FRE.Germany
•
FRE.Italy
•
FREN.Mexico
•
FRE.Switzerland
•
0OO9.UK
•
FSNUF.USA
Description
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care, which accounts for about half of its consolidated revenue. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals in Germany, Spain, and Latin America. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.27 | |||||
| Debt-to-Equity | 1.37 | |||||
| Debt-to-EBITDA | 3.93 | |||||
| Interest Coverage | 8.32 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.96 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.8 | |||||
| 3-Year EBITDA Growth Rate | -0.8 | |||||
| 3-Year EPS without NRI Growth Rate | -3.5 | |||||
| 3-Year FCF Growth Rate | 23.9 | |||||
| 3-Year Book Growth Rate | 7.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 8.33 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 5.12 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32 | |||||
| 9-Day RSI | 29.21 | |||||
| 14-Day RSI | 29.76 | |||||
| 6-1 Month Momentum % | -22.42 | |||||
| 12-1 Month Momentum % | -35.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 0.96 | |||||
| Cash Ratio | 0.15 | |||||
| Days Inventory | 55.55 | |||||
| Days Sales Outstanding | 71 | |||||
| Days Payable | 23.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.75 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| 3-Year Dividend Growth Rate | 5.5 | |||||
| Forward Dividend Yield % | 3.75 | |||||
| 5-Year Yield-on-Cost % | 6.04 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 27.21 | |||||
| Operating Margin % | 10.6 | |||||
| Net Margin % | 4.69 | |||||
| ROE % | 9.69 | |||||
| ROA % | 2.53 | |||||
| ROIC % | 4.68 | |||||
| ROC (Joel Greenblatt) % | 18.06 | |||||
| ROCE % | 7.49 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 7.63 | |||||
| Forward PE Ratio | 7.25 | |||||
| PE Ratio without NRI | 7.64 | |||||
| Shiller PE Ratio | 7.94 | |||||
| Price-to-Owner-Earnings | 9.75 | |||||
| PEG Ratio | 1.82 | |||||
| PS Ratio | 0.36 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Free-Cash-Flow | 5.42 | |||||
| Price-to-Operating-Cash-Flow | 3.04 | |||||
| EV-to-EBIT | 9.3 | |||||
| EV-to-Forward-EBIT | 8.8 | |||||
| EV-to-EBITDA | 5.62 | |||||
| EV-to-Forward-EBITDA | 5.51 | |||||
| EV-to-Revenue | 1.02 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| EV-to-FCF | 15.33 | |||||
| Price-to-Projected-FCF | 0.5 | |||||
| Price-to-DCF (Earnings Based) | 0.42 | |||||
| Price-to-DCF (FCF Based) | 0.4 | |||||
| Price-to-Median-PS-Value | 0.4 | |||||
| Earnings Yield (Greenblatt) % | 10.75 | |||||
| Forward Rate of Return (Yacktman) % | 11.54 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 38,256 | ||
| EPS (TTM) (€) | 3.214 | ||
| Beta | 1.06 | ||
| Volatility % | 26.69 | ||
| 14-Day RSI | 29.76 | ||
| 14-Day ATR (€) | 0.825588 | ||
| 20-Day SMA (€) | 26.2695 | ||
| 12-1 Month Momentum % | -35.42 | ||
| 52-Week Range (€) | 23.4 - 47.507823 | ||
| Shares Outstanding (Mil) | 559.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fresenius SE & Co KGaA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||